1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Lipocine Inc.
  6. Company
    LPCN   US53630X1046

LIPOCINE INC.

(LPCN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Lipocine Inc.
Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. It has a portfolio of product candidates that target unmet needs for neurological and psychiatric central nervous system (CNS) disorders, liver diseases, and hormone supplementation for men and women. The Company's product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its additional pipeline candidates include LPCN 1148, LPCN 1144, LPCN 1111 (TLANDO XR), LPCN 1107, LPCN 1154 and LPCN 2101. ItsLPCN 1144 is an oral prodrug of bioidentical testosterone comprised of TU for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) which has completed Phase II testing. Its TLANDO XR is an oral TRT product comprised of testosterone tridecanoate (TT), which has completed Phase II trials.

Number of employees : 13 people.
Sales per Business
20202021Delta
Oral Delivery Solutions--16.14100%-
USD in Million
Sales per region
20202021Delta
United States--16.14100%-
USD in Million
Managers
Name Title Age Since
Mahesh V. Patel, Dr. Chairman, President, Chief Executive Officer & CFO 64 2022
Anthony DelConte, Dr. Chief Medical Director 63 -
Hans Vitzthum Head-Investors Relation Contact - -
Nachiappan Chidambaram, Dr. Vice President-Product Development 52 2014
Krista Fogarty Chief Accounting Officer 53 2022
Members of the board
Name Title Age Since
Mahesh V. Patel, Dr. Chairman, President, Chief Executive Officer & CFO 64 2022
Richard Dana Ono, Dr. Independent Director 68 2014
Jeffrey Arvin Fink Independent Director 63 2014
Jill M. Jene, Dr. Independent Director 48 2022
Spyros Papapetropoulos Independent Director 48 2022
John W. Higuchi Director 53 2013
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 88,504,834 86,273,957 97.5% 5,710 0.0% 97.5%
Shareholders
NameEquities%
The Vanguard Group, Inc. 3,768,535 4.26%
Wealth Effects LLC 1,489,434 1.68%
BlackRock Fund Advisors 1,285,132 1.45%
Mahesh V. Patel 1,253,090 1.42%
Visium Asset Management LP 904,707 1.02%
Invesco Advisers, Inc. 837,178 0.95%
Geode Capital Management LLC 824,434 0.93%
Cormorant Asset Management LP 741,496 0.84%
John W. Higuchi 693,548 0.78%
Carlson Capital LP 670,000 0.76%
Company contact information
Lipocine, Inc.
675 Arapeen Drive
Suite 202
Salt Lake City, UT 84108

Phone : +1.801.994.7383
Fax : +1.801.994.7388
Web : http://www.lipocine.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Lipocine Inc.
Connections : Lipocine Inc.